NOVOPHARM MARKETING GENERIC RANITIDINE THROUGH AGREEMENT WITH GENPHARM; THREE-WEEK DELAY BRINGS GLAXO $100 MIL. IN ADDITIONAL ZANTAC SALES

Novopharm has begun marketing its generic version of Glaxo Wellcome's Zantac through a commercial agreement with Genpharm. FDA approved Novopharm's ranitidine tablets on July 31.

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Archive

More from Pink Sheet